Indirect CD4+ T-cell-mediated elimination of MHC IINEG tumor cells is spatially restricted and fails to prevent escape of antigen-negative cells

European Journal of Immunology

Volumn 44, Issue 9, 2014, Pages 2625-2637

  Tveita, Anders A ^a   Schjesvold, Fredrik H ^a   Sundnes, Olav ^b   Haabeth, Ole Audun W ^a   Haraldsen, Guttorm ^b   Bogen, Bjarne ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Bystander killing; CD4+ T cell immunotherapy; Macrophage cytotoxicity; Macrophage polarization; Myeloma

Indexed keywords

HLA ANTIGEN CLASS 2;

ANIMAL; ARTICLE; BYSTANDER KILLING; CD4+ T-CELL IMMUNOTHERAPY; CELLULAR IMMUNITY; EXPERIMENTAL NEOPLASM; GENETICS; IMMUNOLOGY; MACROPHAGE; MACROPHAGE CYTOTOXICITY; MACROPHAGE POLARIZATION; MOUSE; MYELOMA; PHYSIOLOGY; SCID MOUSE; TH1 CELL; TRANSGENIC MOUSE;

BYSTANDER KILLING; CD4+ T-CELL IMMUNOTHERAPY; MACROPHAGE CYTOTOXICITY; MACROPHAGE POLARIZATION; MYELOMA;

ANIMALS; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNITY, CELLULAR; MACROPHAGES; MICE; MICE, SCID; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; TH1 CELLS;

EID: 84907821781     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201444659     Document Type: Article

References (42)

1. Muranski, P., Boni, A., Antony, P. A., Cassard, L., Irvine, K. R., Kaiser, A., Paulos, C. M. et al., Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008. 112: 362-373.
2. Xie, Y., Akpinarli, A., Maris, C., Hipkiss, E. L., Lane, M., Kwon, E. K., Muranski, P. et al., Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J. Exp. Med. 2010. 207: 651-667.
3. Fujiwara, H., Fukuzawa, M., Yoshioka, T., Nakajima, H. and Hamaoka, T., The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity. .J Immunol. 1984. 133: 1671-1676.
4. Greenberg, P. D., Kern, D. E. and Cheever,M. A., Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells. J. Exp. Med. 1985. 161: 1122-1134.
5. Quezada, S. A., Simpson, T. R., Peggs, K. S., Merghoub, T., Vider, J., Fan, X., Blasberg, R. et al., Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 2010. 207: 637-650.
6. Mumberg, D., Monach, P. A., Wanderling, S., Philip, M., Toledano, A. Y., Schreiber, R. D. and Schreiber, H., CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc. Natl. Acad. Sci. U S A 1999. 96: 8633-8638.
7. Bogen, B., Munthe, L., Sollien, A., Hofgaard, P., Omholt, H., Dagnaes, F., Dembic, Z. et al., Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies. Eur. J. Immunol. 1995. 25: 3079- 3086.
8. Perez-Diez, A., Joncker, N. T., Choi, K., Chan, W. F. N., Anderson, C. C., Lantz, O. and Matzinger, P., CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007. 109: 5346-5354.
9. Gao, F. G., Khammanivong, V., Liu, W. J., Leggatt, G. R., Frazer, I. H. and Fernando, G. J. P., Antigen-specific CD4(+) T-cell help is required to activate a memory CD8(+) T cell to a fully functional tumor killer cell. Cancer Res. 2002. 62: 6438-6441.
10. Antony, P. A., Piccirillo, C. A., Akpinarli, A., Finkelstein, S. E., Speiss, P. J., Surman, D. R., Palmer, D. C. et al., CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 2005. 174: 2591-2601.
11. Janssen, E. M., Lemmens, E. E., Wolfe, T., Christen, U., von Herrath, M. G. and Schoenberger, S. P., CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003. 421: 852- 856.
12. Tite, J. P. and Janeway, C. A., Jr., Cloned helper T cells can kill B lymphoma cells in the presence of specific antigen: Ia restriction and cognate vs. noncognate interactions in cytolysis. Eur. J. Immunol. 1984. 14: 878-886.
13. Lauritzsen, G. F., Weiss, S., Dembic, Z. and Bogen, B., Naive idiotypespecific CD4+ T cells and immunosurveillance of B-cell tumors. Proc. Natl. Acad. Sci. U S A 1994. 91: 5700-5704.
14. Lundin, K. U., Screpanti, V., Omholt, H., Hofgaard, P. O., Yagita, H., Grandien, A. and Bogen, B., CD4+ T cells kill Id+ B-lymphoma cells: FasLigand-Fas interaction is dominant in vitro but is redundant in vivo. Cancer Immunol. Immunother. 2004. 53: 1135-1145.
15. Qin, Z. H. and Blankenstein, T., CD4(+) T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 2000. 12: 677- 686.
16. Corthay, A., Skovseth, D. K., Lundin, K. U., Røsjø, E., Omholt, H., Hofgaard, P. O., Haraldsen, G. et al., Primary antitumor immune response mediated by CD4+ T cells. Immunity 2005. 22: 371-383.
17. Corthay, A., Lundin, K. U., Lorvik, K. B., Hofgaard, P. O. and Bogen, B., Secretion of yumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells. Cancer Res. 2009. 69: 5901-5907.
18. Haabeth, O. A., Lorvik, K. B., Hammarstrom, C., Donaldson, I. M., Haraldsen, G., Bogen, B. and Corthay, A., Inflammation driven by tumourspecific Th1 cells protects against B-cell cancer. Nat. Commun. 2011. 2: 240.
19. Kerkar, S. P. and Restifo, N. P., Cellular constituents of immune escape within the tumor microenvironment. Cancer Res. 2012. 72: 3125-3130.
20. Garrido, F. and Ruiz-Cabello, F., MHC expression on human tumors-its relevance for local tumor growth andmetastasis. Semin. Cancer Biol. 1991. 2: 3-10.
21. Cabrera, T., Ruiz-Cabello, F. and Garrido, F., Biological implications of HLA-DR expression in tumours. Scand. J. Immunol. 1995. 41: 398-406.
22. Bogen, B., Malissen, B. and Haas, W., Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules. Eur. J. Immunol. 1986. 16: 1373-1378.
23. Bogen, B., Gleditsch, L., Weiss, S. and Dembic, Z., Weak positive selection of transgenic T cell receptor-bearing thymocytes: importance of major histocompatibility complex class II, T cell receptor and CD4 surface molecule densities. Eur. J. Immunol. 1992. 22: 703-709.
24. Dembic, Z., Schenck, K. and Bogen, B., Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells. Proc. Natl. Acad. Sci. U S A 2000. 97: 2697-2702.
25. Lauritzsen, G. F., Weiss, S. and Bogen, B., Anti-tumour activity of idiotype-specific,MHC-restricted Th1 and Th2 clones in vitro and in vivo. Scand. J. Immunol. 1993. 37: 77-85.
26. Dembic, Z., Rottingen, J. A., Dellacasagrande, J., Schenck, K. and Bogen, B., Phagocytic dendritic cells from myelomas activate tumor-specific T cells at a single cell level. Blood 2001. 97: 2808-2814.
27. Lauritzsen, G. F. and Bogen, B., The role of idiotype-specific, CD4+ T cells in tumor resistance against major histocompatibility complex Class II molecule negative plasmacytoma cells. Cell Immunol. 1993. 148: 177-188.
28. Buhtoiarov, I. N., Lum, H., Berke, G., Paulnock, D. M., Sondel, P. M. and Rakhmilevich, A. L., CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro. J. Immunol. 2005. 174: 6013-6022.
29. Egeblad, M., Ewald, A. J., Askautrud, H. A., Truitt, M. L., Welm, B. E., Bainbridge, E., Peeters, G. et al., Visualizing stromal cell dynamics in different tumor microenvironments by spinning disk confocal microscopy. Dis. Model Mech. 2008. 1: 155-167.
30. Huse, M., Lillemeier, B. F., Kuhns, M. S., Chen, D. S. and Davis, M. M., T cells use two directionally distinct pathways for cytokine secretion. Nat. Immunol. 2006. 7: 247-255.
31. Kimachi, K., Croft, M. and Grey, H. M., The minimal number of antigen-major histocompatibility complex class II complexes required for activation of naive and primed T cells. Eur. J. Immunol. 1997. 27: 3310-3317.
32. Schietinger, A., Philip, M., Liu, R. B., Schreiber, K. and Schreiber, H., Bystander killing of cancer requires the cooperation of CD4+ and CD8+ T cells during the effector phase. J. Exp. Med. 2010. 207: 2469-2477.
33. Mantovani, A., Sozzani, S., Locati, M., Allavena, P. and Sica, A., Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002. 23: 549- 555.
34. Biswas, S. K., Gangi, L., Paul, S., Schioppa, T., Saccani, A., Sironi, M., Bottazzi, B. et al., A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 2006. 107: 2112-2122.
35. Mantovani, A., Allavena, P., Sica, A. and Balkwill, F., Cancer-related inflammation. Nature 2008. 454: 436-444.
36. Pollard, J. W., Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 2004. 4: 71-78.
37. Solinas, G., Germano, G., Mantovani, A. and Allavena, P., Tumorassociated macrophages (TAM) as major players of the cancer-related inflammation. J. Leukoc. Biol. 2009. 86: 1065-1073.
38. Duluc, D., Corvaisier, M., Blanchard, S., Catala, L., Descamps, P., Gamelin, E., Ponsoda, S. et al., Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int. J. Cancer 2009. 125: 367-373.
39. Heusinkveld, M., de Vos van Steenwijk, P. J., Goedemans, R., Ramwadhdoebe, T. H., Gorter, A., Welters, M. J., van Hall, T. et al.,M2macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J. Immunol. 2011. 187: 1157-1165.
40. Allavena, P. and Mantovani, A., Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin. Exp. Immunol. 2012. 167: 195-205.
41. Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D. et al., CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma inmice and humans. Science 2011. 331: 1612-1616.
42. Winberry, L., Marks, A. and Baumal, R., Immunoglobulin production and secretion by variant clones of the MOPC 315 mouse myeloma cell line. J. Immunol. 1980. 124: 1174-1182.